01.10.2007 10:30:00
|
Pediatrix Acquires Two Physician Practices
Pediatrix Medical Group, Inc., (NYSE: PDX) has completed the
acquisitions of a neonatal physician group practice based in Nashville,
TN, and a maternal-fetal medicine group practice located in San Luis
Obispo, CA., in two separate transactions, each of which was effective
September 30, 2007.
The six physicians practicing as Neonatologists Professional Service
staff the Level III neonatal intensive care unit (NICU) at Nashville’s
Baptist Hospital. Historical patient volume at that NICU exceeds 9,000
annual patient days.
Central Coast Maternal-Fetal Medicine, Inc., is a three-physician group
specializing in high-risk obstetrics and serving California’s
growing communities in San Luis Obispo, northern Santa Barbara and
southern Monterey counties.
Nashville Neonatology
Neonatologists Professional Service was formed in 1982, and has
maintained a continuous relationship with Baptist Hospital for over 25
years. Among the catalysts for the group to join Pediatrix is their need
for additional infrastructure to support anticipated patient volume
growth, which is expected when the Baptist NICU expands in the near
future.
"The administrative side of a medical practice
has become so complicated over the years,”
said Jorge Rojas, M.D., a founding partner of the practice. Dr. Rojas
will now serve as Pediatrix’s medical
director. "It has become increasingly
difficult for us to dedicate the resources needed to manage in this
environment while maintaining our focus on patient care. As a larger
group, Pediatrix has the experience and the personnel to support our
practice, allowing us to dedicate more resources to taking care of our
patients.”
The neonatologists practicing at Baptist Hospital also expect that as
part of Pediatrix they’ll have more
comprehensive information to help them continuously improve clinical
quality.
"Our ability to gather data in an electronic
note system, and to compare and evaluate our outcomes across the large
base of neonatal units contributing to Pediatrix’s
clinical data warehouse is very attractive,”
Dr. Rojas said.
Pediatrix’s national group of neonatal
physicians includes more than 735 neonatologists who staff more than 240
NICUs. Prior to this acquisition, Pediatrix’s
network in Tennessee included practices in Memphis, Knoxville and
Chattanooga.
San Luis Obispo Maternal-Fetal Medicine
Growth of the San Luis Obispo maternal-fetal medicine practice has
largely been the result of increasing demand from referring
obstetricians for services including high risk pregnancy consultation
and management, prenatal diagnosis, and obstetric ultrasound.
"We have a geographically large referral area
with a growing, younger population, and our practice has expanded based
on the quality of services that our patients receive,”
said Leonard A. Cedars, M.D., who will serve as Pediatrix’s
maternal-fetal medicine medical director and who has been practicing in
San Luis Obispo since 1996. "Our continued
growth will be the result of our ability to maintain our focus on the
expansion of our clinical services, and we expect that Pediatrix’s
clinical and administrative support will help us to better serve our
communities.”
The Central Coast physicians will practice as part of Obstetrix Medical
Group, Pediatrix’s national group of more
than 90 maternal-fetal medicine subspecialists. They also work with the
neonatal physicians practicing as part of Pediatrix who staff the Sierra
Vista Regional Medical Center NICU located in San Luis Obispo.
Pediatrix paid cash for both practices, and they are expected to
immediately contribute to the Company’s
earnings per share. No additional terms were disclosed.
Pediatrix has completed seven physician group practice acquisitions
during 2007, including: three neonatal group practices; a maternal-fetal
medicine practice; one pediatric cardiology practice; an ultrasound
radiology practice; and an anesthesia physician group practice.
About Pediatrix
Pediatrix Medical Group, Inc. is the nation’s
leading provider of neonatal, maternal-fetal and pediatric physician
subspecialty services and recently expanded to include anesthesiology
services. Pediatrix physicians and advanced practitioners are reshaping
the delivery of care within the maternal-fetal, neonatal intensive care
and pediatric cardiology subspecialties, using evidence-based tools,
continuous quality initiatives and clinical research to enhance patient
outcomes and provide high-quality, cost-effective care. Founded in 1979,
its neonatal physicians provide services at more than 240 neonatal
intensive care units, and in many markets they collaborate with
affiliated maternal-fetal medicine, pediatric cardiology physician
subspecialists and pediatric intensivists to provide a clinical care
continuum. Combined, Pediatrix and its affiliated professional
corporations employ more than 1,000 physicians in 32 states and Puerto
Rico. Pediatrix is also the nation’s largest
provider of newborn hearing screens and newborn metabolic screening.
Additional information is available at www.pediatrix.com.
Certain statements and information in this press release may be
deemed to be "forward-looking statements”
within the meaning of the Federal Private Securities Litigation Reform
Act of 1995. Forward-looking statements may include, but are not
limited to, statements relating to our objectives, plans and strategies,
and all statements (other than statements of historical facts) that
address activities, events or developments that we intend, expect,
project, believe or anticipate will or may occur in the future are
forward-looking statements. These statements are often characterized by
terminology such as "believe,” "hope,” "may,” "anticipate,” "should,” "intend,” "plan,” "will,” "expect,” "estimate,” "project,” "positioned,” "strategy”
and similar expressions, and are based on assumptions and assessments
made by Pediatrix’s management in light of
their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe
to be appropriate. Any forward-looking statements in this press release
are made as of the date hereof, and Pediatrix undertakes no duty to
update or revise any such statements, whether as a result of new
information, future events or otherwise. Forward-looking statements are
not guarantees of future performance and are subject to risks and
uncertainties. Important factors that could cause actual results,
developments, and business decisions to differ materially from
forward-looking statements are described in Pediatrix’s
most recent Annual Report on Form 10-K, including the section entitled "Risk
Factors”. Additional factors include, but are
not limited to: the possible discovery of additional facts beyond those
reviewed by the Audit Committee; litigation related to the matters
investigated by the Pediatrix’s Audit
Committee or the restatements to Pediatrix’s
financial statements and other historical disclosures; and any
regulatory actions of the SEC or the U.S. Attorney related to such
matters.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Mednax Incmehr Nachrichten
31.10.24 |
Ausblick: Mednax stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net) | |
17.10.24 |
Erste Schätzungen: Mednax legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) | |
05.08.24 |
Ausblick: Mednax legt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
22.07.24 |
Erste Schätzungen: Mednax veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) |
Analysen zu Mednax Incmehr Analysen
Aktien in diesem Artikel
Mednax Inc | 13,90 | 0,72% |
Indizes in diesem Artikel
S&P 600 SmallCap | 935,46 | -0,94% |